External Influences Upon Ocular Homeostasis
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Jun 15, 2006
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Glaucoma is the second leading cause of blindness in the United States, yet its pathogenesis is poorly understood. This is an insidious disorder since the loss of peripheral vision which occurs first usually is not noticed by the victim. Approximately 1 million people in the United States have glaucoma, but are not aware of it. Glaucoma is not always associated with elevated intraocular pressures so that vision screenings which measure just intraocular pressure without assessing the optic nerve will also miss these patients with glaucomatous damage. Therefore, patients are often diagnosed o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with autonomic dysfunction
- • Patients with open-angle glaucoma
- • Patients with normal-pressure glaucoma
- • Normal subjects
- Exclusion criteria:
- • Medical students
- • Prisoners
- • Pregnant women
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Trial Officials
Karen Joos, MD,PhD
Principal Investigator
Vanderbilt Eye Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials